In today's fast-paced world, many individuals struggle with respiratory issues, whether due to chronic conditions like asthma ...
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...